Arena Pharmaceuticals (ARNA)

ARNA GI / Inflammatory

BiotechSign Signal Grade

Signal Grade

1.2/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying

Publications

100

Clinical Activity

Pipeline Overview

Therapeutic Focus: GI / Inflammatorysrc

Clinical Trial Activity

Clinical Trials
(ClinicalTrials.gov aggregate)

PubMed Publications

Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Recent Publications

Optimising clinical trial design choices in inflammatory bowel disease. — BMJ Open Gastroenterol 2026 Sep 22 Bossuyt P PMID 42772941
A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial. — Dermatol Ther (Heidelb) 2026 Sep 11 Droitcourt C PMID 42728529
Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: The INVESTED-Medicare Linkage Study. — Clin Pharmacol Ther 2026 Sep 6 Cho H PMID 42702729
Total Synthesis-Assisted Structure Determination and Biological Evaluation of Cytotoxic Cyclodepsipeptide Destruxin F. — Chem Pharm Bull (Tokyo) 2026 Shirai D PMID 42702558
Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence: The ADHERE-ASCVD Randomized Clinical Trial. — JAMA 2026 Aug 29 Bhatt AS PMID 42667613

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Arena Pharmaceuticals.

Full ARNA Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.